Drug Discovery

Aardvark Therapeutics secures $85m in Series C funding round

Aardvark Therapeutics has secured $85m in an oversubscribed Series C financing round, with Decheng Capital spearheading the investment, to complete studies of ARD-101.

OverT Bio secures $16m in seed funding for cell therapy development

Data-driven biotechnology company OverT Bio has secured $16m in a seed funding round to expand its discovery platforms aimed at developing cellular therapies for solid tumours.

Latus Bio secures $54m for CNS gene therapy development

Latus Bio, a biotechnology company specialising in new gene therapy candidates for central nervous system (CNS) disorders, has announced its launch alongside an initial $54m Series A financing.

Scenic Biotech, Bristol Myers Squibb to develop new drug targets

Scenic Biotech has entered into a new research partnership with Bristol Myers Squibb, aimed at accelerating the development of new drug targets.

Genmab and Pfizer’s TIVDAK sBLA secures full FDA approval

Genmab and Pfizer have announced that the US Food and Drug Administration (FDA) granted full approval to TIVDAK’s (tisotumab vedotin-tftv) supplemental Biologics License Application (sBLA) to treat patients with recurrent or metastatic cervical cancer who have experienced disease progression on or after chemotherapy.

FDA approves Ractigen Therapeutics’ RAG-01 IND for bladder cancer

Ractigen Therapeutics has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for saRNA therapy RAG-01.

SK pharmteco signs agreement to manufacture Ferring’s ADSTILADRIN

Ferring Pharmaceuticals and SK pharmteco have entered into an agreement to increase commercial manufacturing capacity for Ferring’s ADSTILADRIN (nadofaragene firadenovec-vncg), ensuring a long-term supply of the non-replicating adenoviral vector-based gene therapy.

Telix Pharmaceuticals secures FDA fast track status for TLX101-CDx

Telix Pharmaceuticals has received fast track designation from the US Food and Drug Administration (FDA) for its investigational glioma imaging product, TLX101-CDx (Pixclara).

Immuno-oncology company Portage Biotech to evaluate strategic alternatives

Clinical-stage immuno-oncology company Portage Biotech has announced plans to expand its assessment of strategic alternatives.